Hepatoprotective effects of carvacrol: molecular mechanisms and insights from pre-clinical Studies.

Natural compounds have long been recognized for their therapeutic potential in managing various diseases, including liver disorders. Among these, Carvacrol, a monoterpenoid phenol present in the essential oils of oregano and thyme, has attracted significant attention for its potent hepatoprotective effects. Carvacrol protects the liver by modulating multiple critical molecular pathways. It activates the Nrf2/HO-1 pathway, strengthening the antioxidant defense system and reducing oxidative stress in hepatocytes. It also suppresses NF-κB signaling, resulting in decreased production of pro-inflammatory cytokines such as TNF-α and IL-6, which are key contributors to liver inflammation. Furthermore, carvacrol regulates cell survival and apoptosis through the PI3K/Akt pathway and modulates stress response mechanisms via the MAPK (ERK, JNK, p38) pathway. Preclinical studies in various experimental models of liver injury have consistently suggested its ability to lower serum liver enzyme levels, improve histopathological features, and reduce fibrosis. These multi-targeted effects underscore carvacrol’s broad therapeutic potential as a natural hepatoprotective agent. However, despite promising preclinical results, there is a need for well-designed clinical studies to confirm its efficacy and safety in humans. In addition, due to carvacrol’s limited bioavailability, the development of advanced delivery strategies is crucial to enhance its therapeutic effectiveness. This review aims to comprehensively examine the molecular mechanisms underlying carvacrol’s hepatoprotective activity and discuss its potential clinical applications in supporting liver health.